解释人工智能模型:对LIME和SHAP在阿尔茨海默病检测中的应用进行系统审查
Viswan Vimbi1, Noushath Shaffi1, Mufti Mahmud2,3,4
1College of Computing and Information Sciences, University of Technology and Applied Sciences, OM 311, Sohar, Sultanate of Oman.
Brain informatics
|April 5, 2024
概括
像LIME和SHAP这样的可解释AI (XAI) 方法提高了对阿尔茨海默病检测AI的信任. 这篇评论强调了它们在改善AI预测临床决策方面的作用.
科学领域:
- 人工智能的人工智能
- 机器学习 机器学习
- 深度学习 (Deep Learning) 是一种深度学习.
- 神经科学是一个神经科学.
背景情况:
- 可解释性AI (XAI) 对于理解复杂的机器学习 (ML) 和深度学习 (DL) 模型至关重要.
- 在医疗保健中解释人工智能,特别是用于阿尔茨海默病 (AD) 检测,需要透明的方法.
- 局部可解释的模型不可知解释 (LIME) 和沙普利添加式解释 (SHAP) 是XAI的主要框架.
研究的目的:
- 系统地审查LIME和SHAP在解释阿尔茨海默病检测AI模型中的应用.
- 在AD预后的背景下调查LIME和SHAP的功能,好处和挑战.
- 强调XAI在建立对人工智能驱动的临床决策支持系统的信任方面的作用.
主要方法:
- 系统的文献审查,遵循PRISMA和基奇纳姆的指导方针.
- 识别和分析了23篇关于LIME和SHAP用于AD检测的相关研究文章.
- 深入调查这些XAI框架的潜在能力,好处和挑战.
主要成果:
- XAI框架,特别是LIME和SHAP,越来越多地用于解释用于AD检测的AI模型.
- 这些方法为在AD预后中使用的ML/DL模型的决策过程提供了宝贵的见解.
- 应用LIME和SHAP显著加强了基于AI的AD预测的可靠性.
结论:
- LIME和SHAP是提高AI在AD检测中的忠实性和可解释性的重要工具.
- XAI在推进阿尔茨海默病预后的临床决策支持系统方面发挥着至关重要的作用.
- 进一步研究XAI在临床环境中的实际实施和挑战是有必要的.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.0K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
